Safety of Biologic Therapy

Following completion of this activity, participants should be able to:

• Evaluate the safety of biologic agents and consider how safety should factor into clinical decision making
• Identify clinical strategies based on available evidence for optimizing the use of biologic therapies in the treatment of inflammatory bowel diseases

This educational activity is designed for gastroenterologists and other health care professionals interested in or involved with the management of patients with inflammatory bowel disease.

Participants should read the learning objectives and listen to the activity in its entirety. After reviewing the activity, print out and mail or fax the evaluation and you will receive a letter of credit awarding AMA PRA Category 1 Credit^™ 3 to 4 weeks after receipt of the evaluation.

Estimated time to complete this activity as designed is 0.5 hour.

Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

Temple University School of Medicine is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Temple University School of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit^™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Temple University School of Medicine designates this education activity for a maximum of 0.5 nursing contact hour.

It is the policy of Temple University School of Medicine; The Albert J. Finestone, M.D., Office for Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored or jointly sponsored educational programs. All faculty participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s).

The information presented in this CME activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System, or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, US Food and Drug Administration-approved uses and any off-label uses.

Scott D. Lee, MD, has been a consultant for Abbott Laboratories; Centocor, Inc.; Elan Pharmaceuticals, Inc.; and UCB, Inc. He has received grant/research support from Abbott Laboratories; Centocor, Inc.; Elan Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; and UCB, Inc. He is a member of the speakers bureau for Abbott Laboratories; Centocor, Inc.; Elan Pharmaceuticals, Inc.; and UCB, Inc.

Gary R. Lichtenstein, MD, FACG, has been a consultant for Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Axcan Pharma Inc.; Centocor, Inc.; Elan Pharmaceuticals, Inc.; GlaxoSmithKline; PDL BioPharma, Inc.; Procter & Gamble Pharmaceuticals; Salix Pharmaceuticals, Inc.; Synta Pharmaceuticals Corp.; UCB, Inc.; and Wyeth Pharmaceuticals Inc. He has received grant/research support from Abbott Laboratories; Centocor, Inc.; Millennium Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; PDL BioPharma, Inc.; Salix Pharmaceuticals, Inc.; Schering-Plough Corporation; and Shire US Inc. He is a member of the speakers bureau for Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Centocor, Inc.; Procter & Gamble Pharmaceuticals; Salix Pharmaceuticals, Inc.; and Shire US Inc.

Stephen B. Hanauer, MD, has been a consultant for Abbott Laboratories; Amgen Inc.; Bristol-Myers Squibb Company; Centocor, Inc.; Elan Pharmaceuticals, Inc.; Genentech, Inc.; and Millennium Pharmaceuticals, Inc. He has received grant/research support from Abbott Laboratories; Centocor, Inc.; Elan Pharmaceuticals, Inc.; Genentech, Inc.; and UCB, Inc.

Copyright 2009 Temple University School of Medicine